Pfizer acquires Trillium Therapeutics for $2.22bn
Pfizer has completed the acquisition of all outstanding shares of clinical-stage immuno-oncology firm Trillium Therapeutics in a deal worth about $2.22bn, or $18.50 per share, in cash. The
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorisation by the European regulatory authorities for Novo Nordisk’s anti-obesity medication Wegovy.